Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00699166 · ClinicalTrials.gov registry record · Phase 2

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

A Phase 2 study of Irritable Bowel Syndrome, sponsored by Novartis.

Completed
Registry status
Phase 2
Development phase
135
Enrollment target
20
Study locations

NCT00699166 is a Phase 2 study of Irritable Bowel Syndrome that has completed, run by Novartis. The registered enrollment target is 135 participants, roughly in line with the 141-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target. The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00699166, a Phase 2 study of Irritable Bowel Syndrome, has completed, sponsored by Novartis.

COMPLETED
Registry status
Phase 2
Development phase
135 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the tolerability, safety and efficacy of DNK333 against diarrhea caused by Irritable Bowel Syndrome in women.

Conditions Studied

Irritable Bowel Syndrome

Interventions

  • DRUG DNK333

Study Locations (20)

California

  • - Orange
  • - Riverside
  • - San Diego
  • - Torrance

Alabama

  • - Anniston
  • - Huntsville
  • - Northport

Connecticut

  • - Bristol
  • - Hartford

Missouri

  • - Mexico
  • - Washington

Arizona

  • - Tucson

Arkansas

  • - North Little Rock

Florida

  • - Hollywood

Indiana

  • - Indianapolis

Trial Details

FieldValue
Enrollment Target 135 participants
Start Date 2004-04
Est. Completion 2005-09
Phase Phase 2

Sponsor

Novartis

265 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00699166

The ClinicalTrials.gov registry entry for NCT00699166 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 141-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which DNK333 is the first listed.

NCT00699166 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Alabama, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00699166 about?

NCT00699166 is a clinical study titled "Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)". This study will evaluate the tolerability, safety and efficacy of DNK333 against diarrhea caused by Irritable Bowel Syndrome in women.

What is the current status of trial NCT00699166?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2004-04. Estimated completion is 2005-09.

What conditions does trial NCT00699166 study?

This clinical trial studies the following conditions: Irritable Bowel Syndrome.

What interventions are being tested in trial NCT00699166?

The interventions under investigation include: DNK333 (DRUG).

Who is sponsoring clinical trial NCT00699166?

This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00699166 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Irritable Bowel Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Irritable Bowel Syndrome

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.